Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima 770-8503, Japan.
Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima 770-8503, Japan.
Nutrients. 2021 Jan 23;13(2):335. doi: 10.3390/nu13020335.
A broad range of chronic conditions, including heart failure (HF), have been associated with vitamin D deficiency. Existing clinical trials involving vitamin D supplementation in chronic HF patients have been inconclusive. We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization. This study was based on the Diagnosis Procedure Combination database in the Japanese Registry of All Cardiac and Vascular Datasets (JROAD-DPC). After exclusion criteria, we identified 93,692 patients who were first hospitalized with HF between April 2012 and March 2017 (mean age was 79 ± 12 years, and 52.2% were male). Propensity score (PS) was estimated with logistic regression model, with vitamin D supplementation as the dependent variable and clinically relevant covariates. On PS-matched analysis with 10,974 patients, patients with vitamin D supplementation had lower total in-hospital mortality (6.5 vs. 9.4%, odds ratio: 0.67, < 0.001) and in-hospital mortality within 7 days and 30 days (0.9 vs. 2.5%, OR, 0.34, and 3.8 vs. 6.5%, OR: 0.56, both < 0.001). In the sub-group analysis, mortalities in patients with age < 75, diabetes, dyslipidemia, atrial arrhythmia, cancer, renin-angiotensin system blocker, and β-blocker were not affected by vitamin D supplementation. Patients with vitamin D supplementation had a lower in-hospital mortality for HF than patients without vitamin D supplementation in the propensity matched cohort. The identification of specific clinical characteristics in patients benefitting from vitamin D may be useful for determining targets of future randomized control trials.
大量慢性疾病,包括心力衰竭(HF),与维生素 D 缺乏有关。现有的涉及慢性 HF 患者维生素 D 补充的临床试验尚无定论。我们试图通过使用 HF 住院的真实世界大数据来评估接受维生素 D 补充的患者与匹配队列的结局。这项研究基于日本所有心脏和血管数据集登记处(JROAD-DPC)的诊断程序组合数据库。排除标准后,我们确定了 93692 名于 2012 年 4 月至 2017 年 3 月首次因 HF 住院的患者(平均年龄为 79 ± 12 岁,52.2%为男性)。使用逻辑回归模型估算倾向评分(PS),以维生素 D 补充作为因变量和临床相关协变量。在对 10974 名患者进行 PS 匹配分析后,维生素 D 补充组的总院内死亡率(6.5%比 9.4%,比值比:0.67,<0.001)和 7 天内和 30 天内的院内死亡率(0.9%比 2.5%,比值比:0.34,3.8%比 6.5%,比值比:0.56,均<0.001)均较低。在亚组分析中,年龄<75 岁、糖尿病、血脂异常、房性心律失常、癌症、肾素-血管紧张素系统阻滞剂和β受体阻滞剂的患者的死亡率不受维生素 D 补充的影响。在倾向评分匹配队列中,与未接受维生素 D 补充的患者相比,接受维生素 D 补充的患者的 HF 院内死亡率较低。确定从维生素 D 补充中获益的患者的具体临床特征可能有助于确定未来随机对照试验的目标。